<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332406</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0129</org_study_id>
    <nct_id>NCT04332406</nct_id>
  </id_info>
  <brief_title>Normal Ventilatory and Perfusion Pulmonary Function in TEMP</brief_title>
  <acronym>3DSPECSTAT</acronym>
  <official_title>Normal Ventilatory and Perfusion Pulmonary Function in TEMP: Generation of 3D Statistical Maps From Normal Examinations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilation - perfusion SPECT is attractive for lung function assessement. Unfortunately, it
      is very difficult to delineate normal to abnormal areas because of physiological uptake
      heterogeneity.

      In that context, it would be of interest to build statistical maps from registrered normal
      studies and propose a new methodology for normal SPECT delineation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with normal VQ SPECT-CT will be analysed. After a image proccesing workflow
      including rigid registration, non rigid registration and normalization, a voxelized mean and
      standard deviation map will be created. Those maps will be analyzed in regards of physiology
      and litterature.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Posterior to Anterior and Inferior to Superior uptake relative difference on parametric mean registered SPECT map versus non registered SPECT</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>parametric mean and standard deviation maps are build from elastic registration of normal lung V/Q SPECT-CT. A ROI based quantitative regional uptake comparison is performed to verify the influence of elastic registration on radiotracer distribution</description>
  </primary_outcome>
  <enrollment type="Actual">96</enrollment>
  <condition>Patents With Normal VQ/SPECT</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred to the department of nuclear medicine of Brest University Hospital,
        France, for suspected acute pulmonary embolism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal perfusion and ventilation scans, and no parenchyma or pleural abnormality on
             low dose CT

          -  confirmation by a second senior physician

        Exclusion Criteria:

        Patients with history of pulmonary disease:

          -  chronic obstruction pulmonary disease,

          -  previous pulmonary embolism,

          -  surgery of the lungs

          -  radiotherapy of the lungs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Yves Le Roux, MD, Phd</last_name>
    <role>Study Director</role>
    <affiliation>CHRU Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Médecine nucléaire - Hôpital Morvan (CHRU de Brest)</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

